A Phase 1 interventional study of Cohort 1: AR882 and Cohort 2: AR882 in Healthy Volunteers, sponsored by Arthrosi Therapeutics. Completed at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-16.
Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, double-blind, placebo-controlled, single ascending dose study of AR882 in healthy adult males.
Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cohort 1: AR882
Drug: Cohort 2: AR882 · Drug: Cohort 6: AR882 Food Effect · Drug: Cohort 8: AR882 in combination with allopurinol · Drug: Cohort 9: AR882 in combination with febuxostat
Drug: Cohort 3: AR882
Drug: Cohort 4: AR882
Drug: Cohort 5: AR882
Drug: Cohort 7: AR882 Solid Oral Formulation
Drug: Cohort 1: AR882 · Drug: Cohort 2: AR882 · Drug: Cohort 3: AR882 · Drug: Cohort 4: AR882 · Drug: Cohort 5: AR882 · Drug: Cohort 6: AR882 Food Effect · Drug: Cohort 7: AR882 Solid Oral Formulation
Drug: Cohort 8: AR882 in combination with allopurinol
Drug: Cohort 9: AR882 in combination with febuxostat
Single dose of AR882 or matching placebo
Single dose of AR882 or matching placebo
Single dose of AR882 or matching placebo
Single dose of AR882 or matching placebo
Single dose of AR882 or matching placebo
Single dose of AR882 or matching placebo in a fed state
Single dose of AR882 or matching placebo
Drug pages: AR882 · Allopurinol
Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
Drug pages: AR882 · Febuxostat
Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
To evaluate the safety profile of AR882 based on incidence of abnormal laboratory findings
Analysis of abnormal safety laboratory findings
Time frame: 8 Days
Safety Analyses
ECG Heart Rate
Time frame: 8 Days
Safety Analyses
ECG PR-Interval
Time frame: 8 Days
Safety Analyses
ECG RR-Interval
Time frame: 8 Days
Safety Analyses
ECG QRS-Interval
Time frame: 8 Days
Safety Analyses
ECG QT-Interval
Time frame: 8 Days
Safety Analyses
ECG QTc-Interval
Time frame: 8 Days
Safety Analyses
Vital Sign - Systolic Blood Pressure
Time frame: 8 Days
Safety Analyses
Vital Sign - Diastolic Blood Pressure
Time frame: 8 Days
Safety Analyses
Vital Sign - Pulse Rate
Time frame: 8 Days
Safety Analyses
Vital Sign - Body Temperature
Time frame: 8 Days
Safety Analyses
Vital Sign - Respiratory Rate
Time frame: 8 Days
Area under the curve (AUC) for plasma AR882
Profile from plasma in terms of AUC for AR882
Time frame: 6 Days
Time to maximum plasma concentration (Tmax) for AR882
Profile from plasma in terms of Tmax for AR882
Time frame: 6 Days
Maximum plasma concentration (Cmax) for AR882
Profile from plasma in terms of Cmax for AR882
Time frame: 6 Days
Apparent terminal half-life (t1/2) for AR882
Profile from plasma in terms of t1/2 for AR882
Time frame: 6 Days
Amount excreted (Ae) into urine for AR882
Profile from urine in terms of Ae for AR882
Time frame: 6 Days
Fractional Excretion (FEUA) for AR882
Profile from urine in terms of FEUA for AR882
Time frame: 6 Days
PD profile of a single dose of AR882
Profile from serum uric acid concentrations over time
Time frame: 6 Days
PD profile of a single dose of AR882 in combination with allopurinol
Profile from serum uric acid concentrations over time
Time frame: 6 Days
PD profile of a single dose of AR882 in combination with febuxostat
Profile from serum uric acid concentrations over time
Time frame: 6 Days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2019 to primary completion in Jul 2019, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: AR882 · Allopurinol · Febuxostat